{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["75"],"submitter":["Moncunill G"],"pubmed_abstract":["<h4>Background</h4>Two doses of mRNA vaccination have shown >94% efficacy at preventing COVID-19 mostly in naïve adults, but it is not clear if the second dose is needed to maximize effectiveness in those previously exposed to SARS-CoV-2 and what other factors affect responsiveness.<h4>Methods</h4>We measured IgA, IgG and IgM levels against SARS-CoV-2 spike (S) and nucleocapsid (N) antigens from the wild-type and S from the Alpha, Beta and Gamma variants of concern, after BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccination in a cohort of health care workers (N=578). Neutralizing capacity and antibody avidity were evaluated. Data were analyzed in relation to COVID-19 history, comorbidities, vaccine doses, brand and adverse events.<h4>Findings</h4>Vaccination induced robust IgA and"],"journal":["EBioMedicine"],"pagination":["103805"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8752368"],"repository":["biostudies-literature"],"pubmed_title":["Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naive healthcare workers."],"pmcid":["PMC8752368"],"pubmed_authors":["Vilella A","Garcia-Basteiro AL","Moncunill G","Ribes M","Ortega N","Llupia A","Rodrigo Melero N","Varela P","Aguilar R","Rubio R","Molina MJ","Puyol L","Engel P","Tortajada M","Carolis C","Angulo A","Rodo P","Castellana C","Mitchell RA","Mendez S","Dobano C","Barroso S","Mayor A","Izquierdo L","Trilla A","Jimenez A","Barrios D","Salmeron G","Vidal M","Hernandez-Luis P"],"additional_accession":[]},"is_claimable":false,"name":"Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naive healthcare workers.","description":"<h4>Background</h4>Two doses of mRNA vaccination have shown >94% efficacy at preventing COVID-19 mostly in naïve adults, but it is not clear if the second dose is needed to maximize effectiveness in those previously exposed to SARS-CoV-2 and what other factors affect responsiveness.<h4>Methods</h4>We measured IgA, IgG and IgM levels against SARS-CoV-2 spike (S) and nucleocapsid (N) antigens from the wild-type and S from the Alpha, Beta and Gamma variants of concern, after BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccination in a cohort of health care workers (N=578). Neutralizing capacity and antibody avidity were evaluated. Data were analyzed in relation to COVID-19 history, comorbidities, vaccine doses, brand and adverse events.<h4>Findings</h4>Vaccination induced robust IgA and","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-22T13:16:36.909Z","creation":"2025-02-18T23:26:45.663Z"},"accession":"S-EPMC8752368","cross_references":{"pubmed":["35032961"],"doi":["10.1016/j.ebiom.2021.103805"]}}